Dendritic cell-activated cytokine-induced killer cells - Shenzhen Hornetcorn Biotechnology

Drug Profile

Dendritic cell-activated cytokine-induced killer cells - Shenzhen Hornetcorn Biotechnology

Alternative Names: Ag-D-CIK - Shenzhen Hornetcorn Biotechnology; Autologous dendritic cell cytokine-induced killer cell therapy - Shenzhen Hornetcorn; Autologous tumour lysate-pulsed DCIK - Shenzhen Hornetcorn; DC activated CIK - Shenzhen Hornetcorn Biotechnology; DC-CIK - Shenzhen Hornetcorn Biotechnology; DC-CIK Biotherapy - Shenzhen Hornetcorn Biotechnology; DCIK - Shenzhen Hornetcorn Biotechnology; Dendritic and cytokine-induced killer cells - Shenzhen Hornetcorn; Dendritic cell cytokine-induced killer cell therapy - Shenzhen Hornetcorn

Latest Information Update: 08 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shenzhen Hornetcorn Biotechnology
  • Developer Affiliated Tumor Hospital of Guangzhou Medical University; Shenzhen Hornetcorn Biotechnology
  • Class Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Cytokine induced killer cell inhibitors; Cytokine induced killer cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Gastric cancer; Hepatocellular carcinoma; Oesophageal cancer
  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 01 Feb 2016 Phase I/II clinical trials Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT02651441)
  • 05 Jan 2016 Shenzhen Hornetcorn Bio-technology Company plans a phase I/II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in China (NCT02651441)
  • 01 Dec 2015 Phase-II clinical trials in Oesophageal cancer (Late-stage disease, Combination therapy) in China (IV) (NCT02644863)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top